US equities |
NVDA $181.60 ▼-9.26% MU $656.39 ▼-17.46% AMD $404.40 ▼-17.26% TSLA $343.69 ▼-10.77% AAPL $344.17 ▼-1.53% SNDK $806.43 ▼-22.26% MSFT $535.93 ▼-3.58% AMZN $260.21 ▼-2.19%
FinancialContent

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

13.08 +2.62 (+25.05%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Xeris Biopharma (XERS) Q3 2026 Earnings Call Transcript ↗
Recorlev sales nearly doubled, accelerating a $1 billion target. 
Via The Motley Fool
Topics Earnings Retirement
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Q3 Beat and Raised Guidance Point to Stronger 2026 ↗
Via Chartmill
News headline image
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge ↗
Via Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗
Via Chartmill
News headline image
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for XP-8121 Program Overview Webinar
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris (XERS) Q2 2026 Earnings Call Transcript ↗
Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M. 
Via The Motley Fool
Topics Earnings Intellectual Property Retirement
News headline image
Xeris Biopharma Q2 Earnings Call Highlights ↗
Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of... 
Via MarketBeat
Topics Earnings Retirement
News headline image
Xeris Biopharma Reports Second Quarter 2026 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Updates to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Biopharma Announces Private Exchange of Convertible Notes
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Q1 Earnings Call Highlights ↗
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution... 
Via MarketBeat
Topics Earnings
News headline image
Xeris (XERS) Q1 2026 Earnings Call Transcript ↗
Xeris (XERS) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Xeris Biopharma Reports First Quarter 2026 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >